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Ninety-eight children aged 1-15 years entered a randomized double-blind study investigating an appropriate dose of 
oral prednisolone in children admitted to hospital with an acute exacerbation of asthma. None of the children had 
recently been treated with oral prednisolone. Following admission, the children were randomized to receive 
prednisolone 0.5 mg kg - ‘, 1 .O mg kg - ’ or 2.0 mg kg - ’ in a single daily dose in addition to nebulized bronchodi- 
lators. Clinical asthma scores, oxygen saturations, pulse rate, duration of admission and number of nebulizers given 
were compared in the three treatment groups. 
Thirty-five children received 0.5 mg kg ~ I, 33 received 1.0 mg kg- ’ and 30 received 2.0 mg kg - ‘. There were no 
significant differences in the pattern of recovery between the three treatment groups. There were no advantages in 
using higher doses of prednisolone. We recommend 05 mg kg - r day - ’ of prednisolone as an appropriate dose for 
treating an acute exacerbation of asthma. 
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Introduction 
The first article showing that corticosteroids are effective in 
acute severe asthma was published over 40 yr ago (1). 
Subsequent studies have confirmed this finding in adults 
and in children (2-9). Courses of oral prednisolone for up 
to 5 days are recommended in asthma guidelines in 
adults, the dose being 3MOmg per day. In children the 
recommended dose is l-2 mg kg - ’ day - ‘, (10) a com- 
mensurately higher dose than in adults. There is no 
scientific evidence in the medical literature for the use of 
this dose of prednisolone but concern has been expressed 
about the possible systemic effects following repeated doses. 
For many years in Brighton 2 mg kg - ’ day - ’ of 
prednisolone (11) has been given to children with acute 
asthma needing hospital admission but parents commented 
that their children’s behaviour was sometimes altered 
during the prednisolone treatment. They often appeared 
pale, and some were quiet and unusually reserved while 
others were very active with a short attention span, these 
alterations not being associated with concomitant nebulized 
&agonist inhalations. The prednisolone dose was subse- 
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quently lowered to 1 mg kg - i day ~ ’ but the ward staff 
thought that some children recovered less quickly. 
Although we believed prednisolone to be effective in acute 
severe asthma the present study was undertaken to discover 
whether doses lower than 2 mg kg - ’ day - i were as effec- 
tive but would have less potential for unwanted systemic 
effects. Three doses, 2, 1 and 0.5 mg kg- ’ day- ‘, were 
chosen. 
Patients and Method 
Over a 14 month period all children between the ages of 1 
and 15 years, admitted to the Royal Alexandra Hospital 
with a diagnosis of asthma, were considered for entry into 
this study. Children under 1 year old were not included 
because of diagnostic difficulties in this age group and 
because there is little evidence to demonstrate the efficacy of 
corticosteroids in asthma at this age (11,12). Children were 
excluded if they were already receiving oral corticosteroids, 
if they had been prescribed oral corticosteroids within the 
last 14 days, if they had any significant underlying cardiac 
or pulmonary disease, if the investigating team was un- 
available or if they required intravenous (iv.) therapy at 
the time of admission. For statistical reasons, children with 
repeat admissions were only enrolled in the study once. 
The decision to admit each child was made by the duty 
senior house officer (SHO) depending on response to 5 mg 
nebulized salbutamol, according to the hospital protocol. 
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Once the child had been admitted to the ward, one member 
of the investigating team (S.L.H.) was contacted. Each 
patient was assessed by S.L.H. and, if the diagnosis of 
asthma was confirmed, was invited to join the study. 
Informed written consent was obtained from the parent or 
guardian and from the patient where appropriate. 
Baseline information was recorded, including age, sex, 
personal and immediate family history of asthma and other 
atopic disorders, smoking and any other medical disorders. 
Severity of asthma was assessed at baseline and on regular 
occasions following treatment using a previously described 
clinical asthma score (13) oxygen saturation measure- 
ments and pulse rate. Where possible, peak expiratory 
flow rate (PEFR) and forced expiratory volume in 1 s 
(FEV,) were measured. The clinical asthma score is based 
on auscultatory findings, respiratory effort and patient 
distress, each measured on a O-6 scale giving a maximum 
of 18 points, with higher scores denoting more severe 
symptoms. Oxygen saturation was measured using a 
finger probe with an Ohmeda 3100 saturation monitor 
during quiet breathing of room air. ‘Best of three’ measure- 
ments of PEFR and FEV, were performed using a 
mini-Wright peak flow meter and MicroMedical portable 
printer spirometer. Values for these were compared with 
reference figures (14) and expressed as percentage of 
predicted values. 
Patients were randomized to receive one of three 
prednisolone doses: 0.5, 1.0 or 2.0 mg kg - ’ day - ‘. Doses 
were administered once daily, up to a maximum daily dose 
of 60 mg. Randomization had been previously performed 
by the hospital pharmacist using sealed envelopes disclosing 
the required dose. Stratification of randomization was 
undertaken to ensure approximately equal distributions of 
girls and boys and of older and younger children between 
the three treatment groups. The dose of prednisolone was 
prepared on a different hospital ward and was unknown to 
the investigating team and to the ward staff where the child 
had been admitted. 
Following administration of the first study dose each 
child was reassessed for asthma severity by the same 
investigator (S.L.H.) at 4, 8 and 24 h after treatment and 
twice daily until discharge. Assessments were made 
immediately prior to the administration of nebulized 
bronchodilators and always at least 30 min after the 
previous nebulized treatment. The decision to change from 
nebulized to the child’s usual inhaled therapy and the 
decision to discharge the patient was made by the same 
physician in all cases (S.L.H.). Otherwise, treatment 
during the admission followed the usual hospital protocol. 
Nebulized bronchodilators were given by nursing staff 
every 0.54 h according to need. Prednisolone was given 
daily throughout the child’s hospital stay. 
Patients were withdrawn from the study if they subse- 
quently required i.v. therapy for their asthma control. 
These patients either had oxygen saturations persistently 
below 91% in air or failed to respond adequately to 
nebulized therapy. Patients were also withdrawn if their 
response to therapy was considered to be too slow. Patients 
withdrawn were subsequently treated with 1 .O mg kg - ’ 
day-’ of prednisolone according to the usual hospital 
protocol, with the study team remaining blind to their 
previous study dose of prednisolone. 
Patients were sent home with a 3 day supply of their 
individual study dose of oral prednisolone, their parents 
being instructed to give the child single daily doses, up to 
a maximum of 3 days, if asthma symptoms persisted. 
All patients were given diaries in which to record day and 
night symptom scores, use of inhaled &agonists and, 
when possible best-of-three morning and evening PEFR. 
These diaries were completed for 14 days then returned 
by post to the investigating team. Cough and wheeze 
were scored separately on a l-4 scale (higher scores 
denoting greater symptoms) and the scores were later 
summed. For each child, the total cough and wheeze 
score, the total number of occasions on which relief medi- 
cation was given and the mean percentage of predicted 
PEFR were calculated for days l-7 and 8-14 following 
discharge. 
The code for the dosages of prednisolone given to 
each patient was only broken once all patients had been 
discharged from hospital and their 2 week follow-up 
completed. 
The study had been granted approval by the local ethics 
committee. 
STATISTICAL ANALYSIS 
Sample size calculations were performed using the clinical 
asthma score 4 h after prednisolone treatment as the main 
efficacy variable. Assuming a standard deviation of 3.0 (5), 
a significance level of 5% and a power of 80%, a sample size 
of 40 in each of the groups would allow the detection of 
differences of 1.9 between group means as being statistically 
significant. This was considered to be an appropriate cut-off 
for clinical importance. 
Means for normally distributed data (i.e. oxygen 
saturations, percentage of predicted PEFR and FEV,, pulse 
rate and clinical asthma scores) were compared between 
groups using one-way analysis of variance (ANOVA). 
Skewed data (for duration of admission, the number of 
doses of nebulized therapy and of oral prednisolone and the 
combined cough and wheeze score) were analysed using 
the Kruskall-Wallis test for non-parametric data (15). 
All statistical analyses were performed using a personal 
computer with SPSS statistical software (16). 
Results 
Over the study period 253 children were admitted with a 
diagnosis of asthma on a total of 320 occasions. Informed 
parental consent was obtained for 98 children who were 
subsequently enrolled and randomized. These children had 
30 repeat admissions which were excluded from the study. 
The remaining 155 children were admitted on 192 occasions 
and were not included for the following reasons. The 
investigating team was unavailable for 92 admissions. 
Sixty-seven were already receiving prednisolone prior to 
admission or had received it within the previous 14 days. 
Fourteen were principally admitted for a reason other than 
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TABLE 1. Patient data on entering study [values are mean (standard error), unless stated otherwise] 
0.5mgkgg’ day-‘; 
n=35 
l.Omgkg-’ day-‘; 
n=33 
2.0mgkgg’day-i; 
n=30 
Male (“?) 
Female (%) 
Age (years) 
Height (cm) 
Weight (kg) 
Duration of asthma (yr) 
Family history of atopy (%) 
No. household smokers (%) 
Duration of symptoms for this attack (h) 
Heart rate (beats min - ‘) 
Oxygen saturation (D/o) 
Clinical asthma score 
PEFR (% predicted) 
FEV, (% predicted) 
21 (60) 18 (55) 19 (63) 
14 (40) 15 (45) 11 (37) 
5.39 (0.61) 5.64 (0.60) 5.00 (0.71) 
123 (3.8) 123 (5.1) 124 (7,O) 
(n= 16) (n= 17) (n= 13) 
21.1 (1.86) 21.3 (1.93) 21.3 (2.67) 
2.30 (0.51) 2.42 (0,55) 2.50 (0.61) 
28 (80) 29 (88) 27 (90) 
15 (43) 17 (52) 15 (50) 
47.5 (14.0) 40.5 (22.9) 31.6 (11.7) 
145 (5.51) 143 (4.32) 144 (5.15) 
93.77 (0.36) 93.88 (0.43) 93.30 (0.47) 
9.29 (0.48) 10.21 (0.51 10.12 (0.49) 
68.8 (10.00) 60.0 (8.19) 55.7 (8.04) 
(n= 14) (n= 14) (n=9) 
50.1 (6.48) 44.8 (6.5 1) 45.6 (6.47) 
(n= 14) (n= 14) (n=9) 
asthma. Ten refused to give consent and nine required i.v. - 0.8% to 0.6%; pulse rates, - 7.7 to 17.7, - 15.8 to 
therapy on admission for their asthma. 9 8, - 10.1 to 10.1. 
Of the 98 children enrolled in the study, 35 received 
0.5mgkgg’ day-‘, 33 received 1.0 mg kg - i day - ’ and 
30 received 2.0 mg kg- ’ day - ‘. The patient data are 
shown in Table 1. There were no clinically important 
differences in demographic characteristics, heart rate, 
oxygen saturation, clinical asthma score or pulmonary 
function tests between the three groups at admission. The 
duration of the current asthma attack was slightly shorter 
in those randomized to receive 2.0 mg kg - ’ day - ‘. PEFR 
and FEV, were measured in 37 of the 98 children entering 
the study. 
There were no significant differences between the three 
groups for the median duration of admission or for the 
median number of doses of nebulized therapy or oral 
prednisolone given (Table 3). 
No serious short-term side-effects were noted but 
hyperactivity related to nebulized a-agonist therapy was 
seen in ten children receiving 0.5 mg kg- i day - ‘, seven 
receiving 1 .O mg kg ~ i day ~ ’ and six receiving 2 mg kg - ’ 
Twelve children were withdrawn from the study. In three, 
the response to therapy after 5 days was considered too 
slow (one from each treatment group). Five were given i.v. 
therapy (two received 2 mg kg - ’ day - ‘, 2 received 
l.Omgkg-‘day-‘andonereceived0.5mgkg-’day-’). 
One child was discovered to have previously received 
prednisolone from his general practitioner (1.0 mg group). 
The remaining three, all in the 2 mg prednisolone group, 
were withdrawn because of vomiting, a diagnosis of 
pneumonia or the parents withdrew consent. 
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Changes over time in mean pulse rate, oxygen saturations 
and mean clinical score are shown in Figs 1 and 2. The 
similarity of the results for the three treatment groups does 
not suggest any trend in favour of a dose-response relation- 
ship. There were no significant differences between treat- 
ment group means for any parameter when compared at 4 
and 24 h after the first prednisolone dose and at discharge 
(Table 2). The 95% confidence intervals for the mean 
differences between children on a 0.5 mg dose and those on 
a 2 mg dose at 4 h, 24 h and at discharge were as follows: 
clinical asthma scores, - 2.3 to 0.9, - 2.4 to 0.2, - 1.7 to 
- 0.1; oxygen saturation, 0.2% to 2.2%, - 0.4% to 1.6%, 
- 0 12 24 36 48 60 72 
Time after prednisolone administration (h) 
FIG. 1. Pulse rate and oxygen saturation against time 
after first prednisolone administration: 0.5 (0) 1.0 (0) 
and 2.0 (0) mg kg-’ day-‘. 
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FIG. 2. (a) Clinical score against time after first 
prednisolone administration and (b) clinical score against 
time after first prednisolone administration, for subgroup 
(n=45) who were more severe on admission: 0.5 (O), 1.0 
(0) and 2.0 (0) mg kg day - ‘. 
day - ’ of prednisolone. No side-effect possibly attributable 
to prednisolone therapy was noted in any of the three 
treatment groups. 
A subgroup analysis was performed to examine the 
pattern of recovery in the children whose asthma was most 
severe at the time of admission. The 45 children whose 
admission clinical asthma score values were worse than the 
whole group median were examined. Their improvement 
after admission [Fig. 2(b)] was similar to that for the whole 
group [Fig. 2(a)]. 
Diaries were returned by 61 of the 86 children completing 
the study (71%). The results below are the medians for 
the three treatment doses, in increasing dose order (i.e. 
prednisolone 0.5 mg kg day - ‘, 1.0 mg kg - ’ day - ’ and 
then 2.0 kg mg - ’ day- I). P values are given for the 
comparison of each parameter between the three treatment 
groups. Combined scores for cough and wheeze were higher 
in the first [38, 44, 37 (P=O.lS)] than in the second [24, 19, 
18 (P=O.68)] week. The use of asthma relief medication was 
similar in the first [23, 20, 17 (P=O.73)] and in the second 
[26, 21, 18 (P=O.22)] week. Mean morning percentage 
predicted PEFR (28 children) was lower in the first week 
after discharge [83, 81, 93 (P=O.42)] than in the second 
week [102, 94, 110 (P=O.56)]. Five children were 
re-admitted with an asthma exacerbation within the first 2 
weeks after discharge. Two had received 0.5, one had 
received 1.0 and two had received 2.0 mg kg - ’ day- ’ of 
prednisolone. 
Of the 155 children not entering the study, there were 102 
boys and 53 girls; the median age was 5.2 years (inter- 
quartile range 1.7-7.6 years). The median duration of 
admission was 41 h (23-69 h). The median number of doses 
of nebulized &agonist therapy given was 7 (414) and the 
median number of prednisolone doses given in hospital was 
2 (o-3). 
Discussion 
Over the past 40 years studies comparing corticosteroids 
with placebo in both children and adults with acute asthma 
have usually shown corticosteroids to be of benefit. 
This has resulted in national and international asthma 
management guidelines recommending short courses of 
prednisolone during an acute attack of asthma. Although 
there has been little concern about the short-term systemic 
absorption of corticosteroids there have been worries that 
repeated courses may have a long-term effect on both 
growth and bone biochemistry. It therefore seems pertinent 
to establish whether lower doses of prednisolone are 
equally effective. Inconsistent results from previous studies 
(3,6,17-21) examining steroid dose-response relationships 
might be explained by differences in the population studied 
as well as in the methods used. In some, oral corticosteroids 
were used whereas others used intravenous preparations. 
There are also differences in the additional use of other 
asthma therapies particularly theophyllines and &agonists. 
This study was specifically designed to evaluate three 
doses of oral prednisolone in children admitted to hospital 
with acute asthma in a typical clinical setting as seen in the 
U.K. Not all children in the U.K. receive maximal 
&agonist therapy such as half-hourly nebulized sal- 
butamol or i.v. aminophylline. Therefore our broncho- 
dilator therapy was optimized according to the needs of the 
individual patient. In this way the results of the study 
should be applicable to children with acute asthma in 
general and not just to a specific study population. This 
study is also one of the few to follow patients for 2 weeks 
after discharge. All clinical assessments were undertaken by 
the same physician, thus minimizing observer variation 
in the clinical asthma score and ensuring consistency in 
clinical decision-making when changing from nebulized to 
inhaled P-agonist therapy and in the timing of hospital 
discharge. The investigating physician could not be present 
24 h each day but those children who may have been 
eligible to take part during the study period but were not 
enrolled had similar characteristics to those who did take 
part. Thus we feel that the consistency of one investigating 
physician was preferable to including more children and 
utilizing more staff which is likely to lead to inaccuracies 
and differences of interpretation of clinical features. 
Although the study sample did not reach the desired size 
of 120 children, a lower observed standard deviation 
between clinical asthma scores than the estimate used in the 
sample size calculation (2.7 compared with 3.0) meant that 
the study retained the same power to detect a clinically 
important difference of 1.9 in this variable. 
We have been unable to find any statistically significant 
differences between the three doses of prednisolone used, 
across a range of clinical outcome measures. Although 
this randomized study is relatively small, the confidence 
intervals presented for clinical asthma scores, oxygen 
saturations and pulse rates give reassurance that important 
PREDNISOLONE IN ACUTE CHILDHOOD ASTHMA 545 
TABLE 2. Values for means (standard error) of asthma severity variables at 4 and 24 h from administration of prednisolone 
0.5 mg kg-’ day-‘; l.Omgkg-’ day-‘; 
n=35 n=33 
ANOVA 
P value 
4 h from administration of prednisolone 
Clinical asthma score 7.3 (052) 
(n=33) 
Oxygen saturation 95.1 (0.30) 
(n=33) 
PEFR (% predicted) 80 (16.2) 
(n=6) 
FEV, (% predicted) 58.9 (10.70) 
(n=6) 
Pulse rate (beats min - ‘) 134 (3.61) 
(n=25) 
24 h from administration of prednisolone 
Clinical asthma score 5.4 (0.42) 
(n=32) 
Oxygen saturation 95.7 (0.28) 
(n=32) 
PEFR (% predicted) 81 (9.7) 
(n= 13) 
FEV, (% predicted) 62.7 (6.72) 
(n= 12) 
Pulse rate (beats min - ‘) 125 (4.32) 
(n=23) 
At time of discharge from hospital 
Clinical asthma score 2.4 (0.24) 
(n=31) 
Oxygen saturation 96.7 (0.20) 
(n=32) 
PEFR (% predicted) 99.4 (8.53) 
(n= 15) 
FEV, (% predicted) 77.1 (5.72) 
(n= 15) 
Pulse rate (beats min - ‘) 115 (2.86) 
(n=24) 
7.6 (0.56) 8.0 (0.60) 
(n=30) (n=27) 
94.3 (0.47) 93.9 (0.39) 
(n=30) (n=27) 
60 (14.3) 70 (15.0) 
(n=7) (n=65) 
46.5 (10.38) 53.8 (12.00) 
(n=7) (n=5) 
132 (3.88) 129 (5.34) 
(n=24) (n=22) 
6.2 (0.39) 6.5 (0.52) 
(n=28) (n=24) 
95 3 (0.31) 95.1 (0.44) 
(n=28) (n=24) 
71 (6.1) 87 (6.7) 
(n= 12) (n=9) 
54.4 (4.01) 67.1 (7.97) 
(n=ll) (n=S) 
121 (3.79) 128 (4.61) 
(n=22) (n=20) 
2.6 (0.24) 3.3 (0.35) 
(n=29) (n=23) 
96.7 (0.23) 96.8 (0.32) 
(n=29) (n=24) 
88.7 (7.51) 116.6 (8.60) 
(n=ll) (n=8) 
65.8 (6.95) 79.9 (6.52) 
(n=ll) (n=8) 
120 (3.61) 115 (4.35) 
(n=23) (n= 19) 
0.65 
0.10 
0.63 
0.71 
0.69 
0.19 
0.49 
0.42 
0.38 
0.44 
0.07 
0.96 
0.13 
0.30 
0.48 
TABLE 3. Number of doses of prednisolone and nebulized therapy administered and duration of admission 
Dose of prednisolone given 
0.5 mg kg - * day ~ r; 1 .O mg kg - ’ day - ‘; 2.0 mg kg - r day - ‘; Kruskall-Wallis 
n=35 n=33 ?I=30 P value 
Number of doses of 
prednisolone given in 
hospital, median 
(interquartile range) 
Number of nebulizers 
administered, median 
(interquartile range) 
Duration of admission (h), median 
(interquartile range) 
2 (223) 3 (2-3) 3 (2-3) 0.37 
7 (4-10) 10 (614) 11 (6-14) 0.08 
40.4 47.5 43.1 0.33 
(24.2-52.2) (31.3-61.4) (33.0-59.4) 
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differences have not been missed. Where the extremes of the 
confidence intervals approached levels of clinical signifi- 
cance, the effect was always in favour of the 0.5 mg group. 
Furthermore, when a subgroup was analysed which had 
more clinically severe symptoms on admission than the 
median for the group as a whole, we were still unable 
to show any differences between the three prednisolone 
doses. We are not surprised at these results as it has been 
known for some time that the dose-response curve to 
corticosteroid therapy is relatively flat. 
As stated in local, national and international asthma 
management guidelines, the aim of treatment is to allow the 
patients to lead a normal life, free from symptoms using the 
lowest effective doses of corticosteroids and &-agonist 
therapy. We believe that this aim also applies to the dose of 
oral corticosteroids used in acute asthma. Little is known 
about the long-term consequences of repeated courses of 
oral prednisolone and because of the multifactorial nature 
of asthma, a disease with varying symptoms and multiple 
therapies over long periods of time, it is unlikely that clear 
associations will be easily identified. Over the past 20 yr 
acute symptoms of wheeze have increased tremendously, 
especially in the O-4 year age group. This group accounts 
for nearly 40% of asthma admissions for all age groups 
including adults. Therefore many more pre-school children 
are receiving short courses of prednisolone than in the 
1960s and early 1970s. 
The results of this study suggest that children over 1 year 
old suffering from an acute asthma attack not requiring 
intravenous therapy will respond as effectively to 
0.5mgkgg’ day-’ of prednisolone as they will to higher 
doses of l.Omgkgg’ day-’ or 2.0mgkgg’ day-’ 
of prednisolone. We recommend the routine dose of 
prednisolone for use in short courses in children should be 
0.5mgkgg’day-‘. 
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